Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 36 Show results per page	View Search Criteria \| Help With Results


1.		Arimidex Observational: Reason for and Effect of Change From Tamoxifen

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Completed				18 and over				Pharmaceutical / Industry				D5392NL0002 ARREST, NCT00246961

Last Modified: 1/15/2008 First Published: 8/1/2001


2.		Phase II/III Randomized Study of Anastrozole With or Without Trastuzumab (Herceptin) in Postmenopausal Women With Hormone-Receptor Positive HER2-Overexpressing Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				ROCHE-BO16216 CWRU-030118, GENENTECH-H2223g, ROCHE-1100, ROCHE-B016216F, NCT00022672

Last Modified: 6/1/1998


3.		Phase III Randomized, Double-Blind Study of Anastrozole vs Tamoxifen as First-Line Therapy in Postmenopausal Women with Advanced Breast Cancer (Summary Last Modified 06/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				any age				Pharmaceutical / Industry				ZENECA-1033IL/0030 NCI-V96-1049

Last Modified: 7/18/2005 First Published: 7/1/1998


4.		Phase III Randomized Study of ICI 182780 (Faslodex) versus Anastrozole in Postmenopausal Women with Advanced Breast Cancer (Summary Last Modified 11/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Not specified				NCI, Pharmaceutical / Industry				RPCI-DS-97-29 ZENECA-9238IL/0021, NCI-G98-1412

Last Modified: 8/28/2008 First Published: 1/26/2003


5.		Phase III Randomized Study of Anastrozole Versus Tamoxifen in Postmenopausal Women With Ductal Carcinoma in Situ of the Breast Undergoing Lumpectomy and Radiotherapy (Arm I and Arm II Closed to Accrual as of 6/15/06)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Postmenopausal				NCI				NSABP-B-35 SWOG-NSABP-B-35, NCCTG-NSABP-B-35, ACOSOG-NSABP-B-35, NCT00053898

Last Modified: 1/27/2005 First Published: 1/26/2003


6.		Phase III Randomized Study of Adjuvant Cyclophosphamide, Epirubicin, Fluorouracil, and Docetaxel Versus Observation in Women With Relapsed Nonmetastatic Breast Cancer After Initial Conservative Surgery

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 65				Other				FRE-FNCLCC-PACS-03/003 EU-20237, NCT00053911

Last Modified: 11/3/2008 First Published: 7/26/2003


7.		Phase III Randomized Adjuvant Study of Exemestane Versus Anastrozole in Postmenopausal Women With Receptor-Positive Primary Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Postmenopausal				NCI, Other				CAN-NCIC-MA27 (COMPANION) NCCTG-MA27, CALGB-CAN-NCIC-MA27, ECOG-CAN-NCIC-MA27, SWOG-CAN-NCIC-MA27, NCIC-MA.27, NCT00066573, IBCSG-30-04, EUDRACT-2005-001893-28, MA27


8.		Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Completed				Postmenopausal				Pharmaceutical / Industry				D5392C00050 SABRE, NCT00082277


9.		Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				No age specified				Pharmaceutical / Industry				CFEM345D2411 NCT00248170


10.		Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				No age specified				Pharmaceutical / Industry				D6997L00002 9238SW/0001, FACT, NCT00256698

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute